Abstract:Dirithromycin is a new member of the macrolide class of antibiotics and has been developed for oral administration. Dirithromycin is a 14-membered lactone ring macrolide and is the C9-oxazine derivative of erythromycylamine. The human pharmacokinetics and clinical pharmacology of dirithromycin have been studied. Dirithromycin has unique pharmacokinetics which distinguish it from erythromycin. In man, following an oral 500 mg dose of dirithromycin, a mean peak plasma concentration (Cmax) of 0.48 mg/L (range 0.1-1.97) was observed at 4 h. The mean area under the plasma concentration versus time curve (AUC0-24h) measured 3.37 mg.h/L (range 0.39-17.16). No plasma accumulation was observed with multiple-dose administration. Dirithromycin may be taken without regard to meals, although food and H2-receptor antagonists may increase the systemic bioavailability in some patients. Based upon drug interaction studies performed with antipyrine and theophylline, dirithromycin has shown less potential to interact with other drugs metabolized by the cytochrome P450 system that does erythromycin. Plasma concentrations and AUCs were low due to rapid movement of the drug from the vascular space to the extravascular compartment, as reflected by tissue concentrations, which exceeded plasma concentrations 4 h after dosing. Dirithromycin achieves relatively high tissue concentrations (approximately 0.8-5.0 mg/kg) 4-24 h after dosing. The extensive tissue penetration is reflected in a large mean apparent volume of distribution of 800 L (range 504-1041). Dirithromycin is rapidly converted by non-enzymatic hydrolysis during absorption to erythromycylamine, which is microbiologically active. In a 14C-radiolabelled study, 60-90% of the administered dose was hydrolysed to erythromycylamine within 35 min of infusion. After 1.5 h, conversion to erythromycylamine in serum was virtually complete. Plasma protein binding was determined to be 15-30% by ultracentrifugation. Dirithromycin is characterized by a plasma elimination half-life of 44 h (range 16-65 h) that permits once-daily administration. Total body clearance was 226-1040 mL/min in the 14C-radiolabelled study. The primary route of elimination of dirithromycin/erythromycylamine was faecal/hepatic. Following intravenous administration, approximately 17-25% of the radioactivity appeared in the urine and 62-81% appeared in the stool, indicating predominantly hepatic excretion. With oral administration 1.2-2.9% of the radioactivity appeared in the urine and 81-97% in the stool. The major part of urinary excretion occurs within the first 48 h post-administration; however, urinary excretion of radioactivity lasted longer than 240 h. The absolute bioavailability calculated from dose-corrected urinary excretion data was 10% (6-14%).

Pharmacokinetic Study of Erythromycin Cyclic 11,12-Carbonate Tablets

Bioequivalence Study of Erythromycin Cyclic 11,12-Carbonate Powder Suspension,capsule and Tablet

A randomized, double-blinded, double-modelling and controlled clinical and bacteriological evaluation of erythromycin cyclic 11,12-carbonate in the treatment of bacterial infection compared with roxithromycin

Bioavailability and Bioequivalence of Erythromycin Ethylsuccinate Granules in Healthy Volunteers

Sensitivity study in vitro in clinical isolated strains in the previous five years for erythromycin cyclic 11,12-carbonate

Bioequivalence of erythromycin ethylsuccinate orally disintegrating tablet in healthy volunteers

Bioequivalence of erythromycin enteric-coated capsules in healthy volunteers

Pharmacokinetics and relative bioavalability of clarithromycin tablets

Relative bioavailability of dirithromycin enteric-coated micro-pill capsule in healthy volunteers

Quantitative Analysis of Erythromycylamine in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry and Its Application in a Bioequivalence Study of Dirithromycin Enteric-Coated Tablets with a Special Focus on the Fragmentation Pattern and Carryover Effect.

Pharmacokinetics and Relative Bioavailability of Azithromycin Tabletsin Healthy Volunteers

Bioequivalence of Erythromycin Ethylsuccinate Granules Evaluated by HPLC-MS-MS

Pharmacokinetics and relative bioavailability of clarithromycin tablet in human

The Fate of Erythromycin in Soils and Its Effect on Soil Microbial Community Structure.

Relative Bioavailability of Clarithromycin in Healthy Volunteers

Pharmacokinetics of dirithromycin

Effect of Oral Erythromycin on Gastric and Small Bowel Transit Time of Capsule Endoscopy.

Pharmacokinetics and Bioequivalence of Clarithromycin Controlled-Release Tablets in Healthy Volunteers

A Randomized Controlled Clinical Trial on Injective Azithromycin Versus Erythromycin in the Treatment of Respiratory Tract Bacterial Infections.

Preparation of Erythromycin Nanoemulsion and Determination of Its Bacteriostatic Activity in vitro

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers